Autologous Decidual-like Natural Killer Cells Therapy for Reproductive Failure
A Prospective, Multicenter, Randomized Controlled Clinical Study on Autologous Decidual-like NK Cells Therapy for Reproductive Failure Associated With Abnormal Uterine Natural Killer Cells
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Yali Hu
- Phone Number: 11201 86-025-83106666
- Email: glyyhuyali@163.com
Study Contact Backup
- Name: Hui Zhu
- Phone Number: 54330 86-025-8310666
- Email: zhuhui1231@126.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Reproductive failure with abnormal endometrial natural killer (NK) cells in menstrual blood;
- With a clear intention to conceive;
- Normal ovarian function, or premature ovarian insufficiency with ≥2 high-quality cryopreserved embryos available for transfer;
- Endometrial thickness measured by transvaginal ultrasound during the periovulatory period ≥7 mm;
- Body mass index (BMI) between 18 kg/m² and 28 kg/m²;
- Willing to comply with the follow-up plan of this study.
Exclusion Criteria:
- Use of progesterone receptor modulators;
- One of the couple's chromosomal karyotype abnormalities, with no euploid embryo identified via preimplantation genetic testing for aneuploidy;
- Severe endometriosis or adenomyosis, uterine fibroids affecting uterine cavity morphology, uterine malformations, intrauterine adhesions, or thin endometrium;
- Uncontrolled autoimmune or endocrine disorders;
- Contraindications to pregnancy;
- History of malignant tumors;
- Participating in other clinical studies;
- Allergy to blood products.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: NK cell perfusion group
Accepting NK cell therapy
|
Completing two rounds of NK cell therapy
|
|
No Intervention: Control group
Not accepting NK cell therapy
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Ongoing pregnancy rate
Time Frame: 6 months, if a participant is confirmed to get a clinically pregnancy during this period, the follow-up endpoint will be extended until there is a pregnancy outcome
|
Ongoing pregnancy is defined as at least 12 weeks of gestation, with ultrasound indicating fetal cardiac activity and fetal size consistent with the gestational age
|
6 months, if a participant is confirmed to get a clinically pregnancy during this period, the follow-up endpoint will be extended until there is a pregnancy outcome
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Improvement rate of NK cells
Time Frame: 6 months
|
Improvement rate of NK cells in menstrual blood analysis after intrauterine perfusion of autologous decidual-like NK cells
|
6 months
|
|
Clinical pregnancy rate
Time Frame: 6 months
|
Clinical pregnancy is defined as the presence of a gestational sac in the uterine cavity as indicated by ultrasound at 5-7 weeks of gestation
|
6 months
|
|
Miscarriage rate
Time Frame: 6 months, if a participant is confirmed to get a clinically pregnancy during this period, the follow-up endpoint will be extended until there is a pregnancy outcome
|
Miscarriage is defined as the pregnancy loss before 28 weeks of gestation
|
6 months, if a participant is confirmed to get a clinically pregnancy during this period, the follow-up endpoint will be extended until there is a pregnancy outcome
|
|
Preterm birth rate
Time Frame: 6 months, if a participant is confirmed to get a clinically pregnancy during this period, the follow-up endpoint will be extended until there is a pregnancy outcome
|
Preterm birth is defined as delivery at 28 to 37 weeks of gestation
|
6 months, if a participant is confirmed to get a clinically pregnancy during this period, the follow-up endpoint will be extended until there is a pregnancy outcome
|
|
Live birth rate
Time Frame: 6 months, if a participant is confirmed to get a clinically pregnancy during this period, the follow-up endpoint will be extended until there is a pregnancy outcome
|
Live birth is defined as delivery of any number of neonates born at 26 or more weeks' gestation with signs of life
|
6 months, if a participant is confirmed to get a clinically pregnancy during this period, the follow-up endpoint will be extended until there is a pregnancy outcome
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Yali Hu, The Affiliated Drum Tower Hospital of Nanjing University
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SC2025-0013-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.